Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022GlobeNewsWire • 03/03/22
Fortress Biotech to Participate in the 2nd Annual Winter Wonderland Best Ideas Virtual Investor ConferenceGlobeNewsWire • 02/07/22
Fortress Biotech to Participate in the H.C. Wainwright BioConnect Virtual ConferenceGlobeNewsWire • 01/06/22
Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMVGlobeNewsWire • 12/16/21
Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce the Initiation of Rolling Submission of a New Drug Application for CUTX-101, Copper Histidinate, for Treatment of Menkes DiseaseGlobeNewsWire • 12/07/21
Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/15/21
Fortress Biotech (FBIO) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 11/01/21
Fortress Biotech to Participate in Dawson James Securities' 6th Annual Small Cap Growth ConferenceGlobeNewsWire • 10/18/21
Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & ExhibitionPRNewsWire • 10/13/21
Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZenecaGlobeNewsWire • 10/06/21
Journey Medical Corporation Appoints Ernest De Paolantonio as Chief Financial OfficerGlobeNewsWire • 10/05/21
Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences, a Company Founded by Fortress BiotechGlobeNewsWire • 09/29/21
Fortress Biotech Reports Record Second Quarter 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 08/16/21
Fortress Biotech (FBIO) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 08/02/21